Clinical_Trials
The latest news about Clinical_Trials: headlines, AI summaries and the full story from every source.
- Florida Cancer Specialists Contributes to FDA Approvals for Breast and Pancreatic Cancer Treatments
- Nutriband Raises $1.75 Million from Warrant Exercises to Fund AVERSA Fentanyl Development
- Pomerantz Law Firm Investigates Potential Securities Fraud at Tyra Biosciences
- BridgeBio's Infigratinib Receives Priority Review for Achondroplasia
- Eli Lilly's Jaypirca receives FDA approval for first-line treatment of certain leukemia and lymphoma cases
- Pomerantz Law Firm Investigates SELLAS Life Sciences Group for Potential Securities Fraud
- Viking Therapeutics Shares Drop After Oversubscribed Capital Raise
- Gossamer Bio Submits NDA for Seralutinib in Pulmonary Arterial Hypertension
- Ionis Pharmaceuticals Stock Falls Over 40% This Year Despite Analysts' Bullish Outlook
- Amgen Stock Drops Sharply Amid Novartis' Lp(a)-Lowering Drug Failure
- Ovid Therapeutics Reports Financial Results and Pipeline Updates
- Investor Alert: Tyra Biosciences Faces Securities Fraud Investigation by Pomerantz Law Firm
- Roivant Sciences Shares Rise After Positive PH-ILD Trial Results
- Amgen Shares Drop Amid Mixed News from Lp(a) Trials and BMO Downgrade
- Revolution Medicines Prices New Pancreatic Cancer Drug at $39,800 per Month
- Revolution Medicines Achieves FDA Approval for Rasonque, Reaching $47B Valuation
- ADC Therapeutics Faces FDA Concerns Over ZYNLONTA Combination While Reducing Losses
- Lantern Pharma Reports Q2 2026 Financials and Clinical Progress
- Longeveron Reports Q2 2026 Financial Results and Provides Clinical Update
- BioMarin Acquires Alesta Therapeutics for $275 Million to Expand Rare Disease Pipeline
- Atea (AVIR) Q2 2026 Earnings Call Summary
- BioMarin Acquires Alesta Therapeutics for $275 Million in Deal with Potential Additional Payments
- Premarket Stock Movements: Moderna, Merck Surge on Cancer Vaccine Trial Results
- Moderna Reports Narrower Q2 Net Loss but Norovirus Vaccine Fails Interim Analysis
- Kiniksa Pharmaceuticals Reports Strong Q2 Earnings and Raised Revenue Guidance
- Omeros Gains as AstraZeneca's Ultomiris Fails in Rare Blood Disorder Trial
- Regeneron Faces Securities Class Action Over Failed Melanoma Trial
- Zephyr Energy, Quantum Blockchain, Pathos Communications, AOTI, Scancell - Small Cap Update
- Shattuck Labs Shares Rise Over 4% After JPMorgan Analyst Issues Buy Rating
- Eli Lilly Acquires AtaiBeckley in $2.8 Billion Deal
- Pfizer Announces FDA Approval for PADCEV Plus Keytruda Combination Therapy for Muscle-Invasive Bladder Cancer
- Agenus Secures Up to $340M Financing for Colon Cancer Trial, Shares Surge
- FDA Accepts sNDA for Full Approval of BioMarin’s Voxzogo
- AbbVie's Skyrizi Approved for Pediatric Psoriatic Disease
- Lantheus Receives Complete Response Letter from FDA for LNTH-2501
- Siren Biotechnology Receives $8M Grant from CIRM to Support Clinical Development of SRN-101 for High-Grade Glioma
- MacroGenics Receives $24.5M Milestone Payment from Sanofi Following Tzield Approval
- Achieve Life Sciences Shares Rise Despite FDA CRL for Smoking Cessation Drug
- Summit Therapeutics Withdraws $500 Million Stock Offering Due to Unfavorable Market Conditions
- Armata Pharmaceuticals Receives FDA Fast Track Designation for AP-SA02
- Abivax Reports Q1 2026 Financial Results with Extended Cash Runway
- Vera Therapeutics Reaches FDA Agreement, Accelerating Approval Timeline for Atacicept in IgA Nephropathy
- Grail Stock Faces Volatility After NHS Trial Results Miss Expectations
- Grail Shares Drop After Mixed Results from NHS-Galleri Trial Presented at ASCO
- Curis Reports Q1 2026 Earnings with Net Loss of $24.2 Million
- Advanced NanoTherapies cierra una ronda de financiación Serie B por más de $31 millones para desarrollar su plataforma de balón recubierto con doble fármaco
- Advanced NanoTherapies obtains over $31 million in Series B funding for dual-drug nanoparticle-coated balloon therapy
- AstraZeneca's CARES Phase III Clinical Programme Fails to Meet Primary Endpoint
- INmune Bio Reports Q4 2025 Earnings with Increased Net Loss but Progress on Key Programs
- DiaMedica Reports Q4 2025 Earnings with Updated Financials and Clinical Progress